CAMBIA
What it isDiclofenac potassium 50 mg powder for oral solution (CAMBIA, 2009) — buffered solution absorbed faster than tablets, labeled for acute migraine with or without aura in adults.
Why this oneSame molecule and receptor pharmacology as the parent card — the formulation (and its label) is the difference.
What limits itClass warnings of the parent molecule apply unchanged.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Acute treatment of migraine (with or without aura); not for prophylaxis | Adults >=18 yr | 50 mg (one packet) once, dissolved in 30–60 mL (1–2 oz) water | Single 50 mg dose | Single 50 mg dose (second dose not established) |
Renal Monitor renal function in renal impairment; avoid in advanced renal disease unless benefits outweigh risks
Hepatic Use only if benefits outweigh risks (diclofenac elimination is almost entirely hepatic); monitor for hepatotoxicity
Safety and effectiveness of a second dose have not been established
Pregnancy Avoid at ~30 weeks gestation and later (premature closure of fetal ductus arteriosus); limit use 20–30 weeks (risk of oligohydramnios/fetal renal dysfunction).
Lactation Small amounts of diclofenac present in human milk; effects on infant/milk production unknown.
⚠ BOXED WARNINGS

Open Diclofenac oral solution in the interactive console ↗

